Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BOPHNYSE:NAVBOTCMKTS:NRXGQOTCMKTS:XSNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOPHBohai Pharmaceuticals Group$0.00$0.00$0.00▼$0.00$20K1.7830,425 shs50,000 shsNAVBNavidea Biopharmaceuticals$0.00+50.0%$0.00$0.00▼$0.13$30K1.758,709 shs8,000 shsNRXGQNephroGenex$0.00$0.00▼$0.21$36KN/A26,223 shs2,000 shsXSNXNovAccess Global$0.00$0.00$0.00▼$0.02$13K3.28,836 shs150 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOPHBohai Pharmaceuticals Group0.00%0.00%0.00%0.00%0.00%NAVBNavidea Biopharmaceuticals0.00%-80.00%-71.43%-66.67%-80.00%NRXGQNephroGenex0.00%0.00%0.00%0.00%0.00%XSNXNovAccess Global0.00%0.00%+200.00%0.00%-97.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBOPHBohai Pharmaceuticals GroupN/AN/AN/AN/AN/AN/AN/AN/ANAVBNavidea BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ANRXGQNephroGenexN/AN/AN/AN/AN/AN/AN/AN/AXSNXNovAccess GlobalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBOPHBohai Pharmaceuticals Group 0.00N/AN/AN/ANAVBNavidea Biopharmaceuticals 0.00N/AN/AN/ANRXGQNephroGenex 0.00N/AN/AN/AXSNXNovAccess Global 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBOPHBohai Pharmaceuticals GroupN/AN/AN/AN/AN/AN/ANAVBNavidea Biopharmaceuticals$8.13K3.69N/AN/AN/A∞NRXGQNephroGenexN/AN/AN/AN/AN/AN/AXSNXNovAccess GlobalN/AN/AN/AN/A($0.58) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBOPHBohai Pharmaceuticals GroupN/AN/A0.00∞N/AN/AN/AN/AN/ANAVBNavidea Biopharmaceuticals-$15.18MN/A0.00∞N/AN/AN/AN/AN/ANRXGQNephroGenexN/AN/A0.00N/AN/AN/AN/AN/AN/AXSNXNovAccess Global-$4.72M-$0.11N/A∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBOPHBohai Pharmaceuticals GroupN/AN/AN/AN/AN/ANAVBNavidea BiopharmaceuticalsN/AN/AN/AN/AN/ANRXGQNephroGenexN/AN/AN/AN/AN/AXSNXNovAccess GlobalN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBOPHBohai Pharmaceuticals GroupN/ANAVBNavidea Biopharmaceuticals0.01%NRXGQNephroGenexN/AXSNXNovAccess GlobalN/AInsider OwnershipCompanyInsider OwnershipBOPHBohai Pharmaceuticals GroupN/ANAVBNavidea Biopharmaceuticals43.68%NRXGQNephroGenexN/AXSNXNovAccess Global1.44%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBOPHBohai Pharmaceuticals GroupN/A19.52 millionN/ANot OptionableNAVBNavidea Biopharmaceuticals10100.08 million56.37 millionOptionableNRXGQNephroGenex1,70012.95 millionN/ANot OptionableXSNXNovAccess Global244.60 million43.96 millionNot OptionableXSNX, NRXGQ, BOPH, and NAVB HeadlinesRecent News About These CompaniesGlobal wage calculator: Compare your salaryNovember 14, 2024 | money.cnn.comNovAccess Global Inc.August 28, 2024 | wsj.comNovAccess Global Inc. (XSNX)July 21, 2024 | finance.yahoo.comNovAccess Global Files Patent with Cedars-Sinai to Advance its Brain Cancer Fighting Vaccine PlatformMay 21, 2024 | finance.yahoo.comNovAccess Global Inc.: NovAccess Global Advisory on Annual Meeting of ShareholdersMay 7, 2024 | finanznachrichten.deNovAccess Global Advisory on Annual Meeting of ShareholdersMay 7, 2024 | accesswire.comANovAccess Global Announces New License to Advance its Immunotherapy PlatformApril 30, 2024 | finance.yahoo.comNovAccess Global Announces New License to Advance its Immunotherapy PlatformApril 30, 2024 | accesswire.comANovAccess Global Provides Business Updates and Announces Scheduling of Annual Meeting of ShareholdersMarch 1, 2024 | accesswire.comANovAccess Global Faces Default and Uncertain Rescue DealFebruary 7, 2024 | msn.comNovAccess Global jumps on announcing $10.7 million financingJanuary 2, 2024 | msn.comNovAccess Global Inc.: NovAccess Global Announces $10.7 Million FinancingJanuary 2, 2024 | finanznachrichten.deNovAccess Global Announces $10.7 Million FinancingJanuary 2, 2024 | finance.yahoo.comNovAccess Global Inc. to Present at the December 7th Virtual Investor SummitDecember 1, 2023 | finance.yahoo.comNovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory BoardNovember 10, 2023 | finance.yahoo.comNovaccess Global Inc XSNXNovember 2, 2023 | morningstar.comMBack to the Trend? Global Debt Evolution Before and After the PandemicSeptember 13, 2023 | imf.orgINovAccess Global Inc.: NovAccess Global Partners with BCN Biosciences to Expand Immunotherapy PlatformJuly 29, 2023 | finanznachrichten.deNovAccess Global Partners with BCN Biosciences to Expand Immunotherapy PlatformJuly 27, 2023 | finance.yahoo.comNovAccess Global to Participate in National Brain Tumor Society's Annual Glioblastoma Awareness DayJuly 13, 2023 | finance.yahoo.comXSNX, NRXGQ, BOPH, and NAVB Company DescriptionsBohai Pharmaceuticals Group OTCMKTS:BOPH$0.0010 0.00 (0.00%) As of 03/11/2019Bohai Pharmaceuticals Group, Inc. engages in the production, manufacture, and distribution of herbal pharmaceuticals based on traditional Chinese medicine. Its products include lung nourishing syrup, tongbi capsules, tongbi tablets, zhuangyuanshenhailong medicinal wine, bazhenyimu cream, fangfengtongsheng granule, and zhengxintai capsules. The company was founded on January 9, 2008 and is headquartered in Yantai, China.Navidea Biopharmaceuticals NYSE:NAVB$0.0003 +0.00 (+50.00%) As of 01:30 PM EasternNavidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.NephroGenex OTCMKTS:NRXGQNephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.NovAccess Global OTCMKTS:XSNX$0.0003 0.00 (0.00%) As of 01:03 PM EasternNovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. The company was incorporated in 1997 and is headquartered in Chagrin Falls, Ohio. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
